LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
Lindis Biotech GmbH / Key word(s): Regulatory Approval LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES 13.02.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLYLINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER
UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE EXCLUSIVE RIGHTS TO BRING CATUMAXOMAB TO MARKET AND TO LEAD ALL ACTIVITIES TO LAUNCH CATUMAXOMAB ACROSS EUROPE
THIS MARKS ANOTHER MILESTONE FOR PHARMANOVIA, AS IT DEEPENS ITS FOOTPRINT WITHIN SPECIALTY PHARMACEUTICALS
MUNICH, GERMANY, AND BASILDON, UK, 13 February 2025LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline in immuno-oncology, and Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.Under a licensing agreement, LINDIS has granted Pharmanovia the exclusive rights to bring catumaxomab to market and spearhead its launch across Europe.Catumaxomab, a first-in-class therapeutic, is specifically designed to treat malignant ascites in adults with certain types of cancer (epithelial cellular adhesion molecule (EpCAM)-positive carcinomas) who are not eligible for other systemic anticancer therapies. Malignant ascites is a serious complication of advanced-stage cancers, characterised by the buildup of fluid in the abdomen, causing significant discomfort and severely impacting quality of life. The condition leads to considerable symptoms such as abdominal distension, pain, shortness of breath, fatigue, and fever.Stephen Deacon, Chief Scientific Officer at Pharmanovia commented; 'This European Commission approval of catumaxomab is a significant milestone for people living with malignant ascites.Catumaxomab represents a novel therapeutic approach to this challenging condition. By targeting tumour cells and harnessing the power of the patient's own immune system, we aim to improve quality of life for those living with malignant ascites in Europe."Pharmanovia CEO, Dr. James Burt, highlighted the broader implications of the approval; 'This approval not only brings a much-needed treatment to people with malignant ascites but also exemplifies Pharmanovia's commitment to deepening our footprint within the specialty pharmaceutical sector. We are dedicated to delivering innovative and improved medicines to people in need, and this approval reinforces our position as a leader in providing access to essential therapies."Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech, added: 'We are delighted to receive marketing approval for catumaxomab. The approval highlights its potential to address the significant medical and treatment challenges faced by patients with malignant ascites. These individuals often endure invasive procedures like paracentesis, which carry risks of complications and severely impact their quality of life. Partnering with Pharmanovia to support commercialization, we are committed to ensuring that this groundbreaking therapy becomes accessible to all patients who can benefit from it.'-Ends-Notes to editorsAbout PharmanoviaPharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.Lindis BiotechLindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases.About CATUMAXOMABCatumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons.On 17th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®.Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body's immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect. ,The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial cancer) and is also known as a marker on tumor initiating cancer stem cells – a main driver of metastasis. Therefore, it is a promising approach for targeted treatment of various carcinomas.For more information please contact: Pharmanovia Alison Dyson Director of Communications, Pharmanovia Tel.: 07912887250 E-Mail: orLINDIS Biotech GmbH Dr. Horst Lindhofer CEO E-Mail: Website:Media inquiries MC Services AG Anne Hennecke Tel.: +49 (0) 211-529-252-22 E-Mail:References Korjuny | European Medicines Agency (EMA) (2024) European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny (Accessed: 11 December 2024). Ascites and Cancer - Side Effects (2024) Cancer.gov. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/ascites#signs-and-symptoms-of-ascites (Accessed: 11 December 2024). Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1–10; 2013
13.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Inflection Point Acquisition Corp. III Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on or about June 16, 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. III (Nasdaq: IPCXU) (the 'Company') announced that holders of the units sold in the Company's initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on April 28, 2025 (the 'Offering') may elect to separately trade the Class A ordinary shares and rights included in the units commencing on or about June 16, 2025. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol 'IPCXU', and each of the Class A ordinary shares and rights will separately trade on The Nasdaq Global Market under the symbols 'IPCX' and 'IPCXR,' respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and rights. The Company intends to pursue a business combination with a North American or European business in disruptive growth sectors, which complements the expertise of its management team, but may pursue an initial business combination in any industry, sector or geographic region. The company is led by Chairman and Chief Executive Officer Michael Blitzer, Chief Financial Officer Peter Ondishin and Chief Operating Officer Kevin Shannon. A registration statement relating to the securities was declared effective on April 24, 2025 in accordance with Section 8(a) of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. About Inflection Point Acquisition Corp. III Inflection Point Acquisition Corp. III's acquisition and value creation strategy is to identify, partner with and help grow North American and European businesses in disruptive growth sectors, which complements the expertise of its management team. However, the Company may pursue an initial business combination in any industry, sector or geographic region. Contact Kevin ShannonInflection Point Acquisition Corp. IIIkevin@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Nvidia (NVDA) to Build First Industrial AI Cloud in Germany
Nvidia (NVDA, Financials) will develop its first industrial AI cloud in Germany to support applications ranging from automotive design to logistics optimization, CEO Jensen Huang said Wednesday at the VivaTech conference in Paris. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The platform will help industrial firms such as BMW and Mercedes-Benz simulate production processes and integrate robotics with artificial intelligence. Biotech companies like Novo Nordisk (NVO, Financials) are also expected to benefit, using Nvidia's tools for drug discovery. Huang said Nvidia will multiply its AI computing capacity in Europe tenfold over the next two years and will open 20 AI factorieslarge-scale infrastructure facilities for building and deploying AI models. He described Europe as newly "awakened" to the importance of sovereign AI development. Nvidia will also expand its technology centers across seven countries, launch a European compute marketplace, and partner with AI startups such as France-based Mistral to run models on 18,000 Nvidia chips. The project aligns with the European Commission's own investment initiative, which earmarked $20 billion in March for building AI factories. Huang emphasized that no country or company can afford to "outsource its intelligence." Separately, Huang reiterated his recent comments that quantum computing is reaching an inflection point and could solve real-world problems within a few years, reversing his prior view that useful quantum systems remain decades away. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Major airlines may have been secretly selling your flight data to DHS, report claims
Americans' flight data may have been sold to Customs and Border Protection (CBP) without their knowledge, internal CBP documents obtained by 404 Media suggest. A data broker, the Airlines Reporting Corporation (ARC), owned by several of the top airlines in the U.S., including Delta, American Airlines, and United, reportedly gathered the flight records of U.S. travelers and sold access to CBP. Part of the contract was that CBP wasn't allowed to share where the data had originated from, the report says. The data included passengers' names, itineraries, and financial information, according to Wired. CBP is part of the Department of Homeland Security. The agency has stated that it requires the data to support state and local law enforcement in tracking individuals of interest. This comes after Immigration and Customs Enforcement (ICE) outlined how it also bought the data. 'The big airlines—through a shady data broker that they own called ARC—are selling the government bulk access to Americans' sensitive information, revealing where they fly and the credit card they used,' Democratic Sen. Ron Wyden said in a statement. "ARC has refused to answer oversight questions from Congress, so I have already contacted the major airlines that own ARC—like Delta, American Airlines, and United—to find out why they gave the green light to sell their customers' data to the government." Publicly shared documents show that ARC is owned and operated by at least eight top U.S. airlines. Delta, Southwest, United, American Airlines, Alaska Airlines, JetBlue, as well as European airlines Lufthansa and Air France, in addition to Air Canada, all have representatives on the company's board of directors. Over 240 airlines use ARC's services for ticket settlement. The company also connects airlines and travel agencies, locating travel trends with other companies such as Expedia. It also provides fraud prevention, the ARC YouTube channel and website show. The selling of travel information is conducted via the company's Travel Intelligence Program (TIP). The documents obtained by 404 Media via a Freedom of Information Act request state that CBP needed access to the information 'to support federal, state, and local law enforcement agencies to identify persons of interest's US domestic air travel ticketing information.' The documents reveal that ARC asked CBP to 'not publicly identify vendor, or its employees, individually or collectively, as the source of the Reports unless the Customer is compelled to do so by a valid court order or subpoena and gives ARC immediate notice of same.' The data delivers 'visibility on a subject's or person of interest's domestic air travel ticketing information as well as tickets acquired through travel agencies in the U.S. and its territories,' the documents state. According to a DHS Privacy Impact Assessment, the data is updated daily and includes more than a billion records over the course of 39 months of travel, both past and future. TIP can be searched using names, credit cards, or airlines. However, the data only includes travel arrangements made using a travel agency accredited by ARC, such as Expedia. 'If the passenger buys a ticket directly from the airline, then the search done by ICE will not show up in an ARC report,' the assessment states. It also says that data is included on both U.S. and non-U.S. persons. The deputy director of the Center for Democracy & Technology's Security and Surveillance Project, Jake Laperruque, told 404 Media that 'While obtaining domestic airline data—like many other transaction and purchase records—generally doesn't require a warrant, they're still supposed to go through a legal process that ensures independent oversight and limits data collection to records that will support an investigation.' 'The government seems intent on using data brokers to buy their way around important guardrails and limits,' he added. A spokesperson for CBP told Wired that the agency 'is committed to protecting individuals' privacy during the execution of its mission to protect the American people, safeguard our borders, and enhance the nation's economic prosperity.' 'CBP follows a robust privacy policy as we protect the homeland through the air, land and maritime environments against illegal entry, illicit activity or other threats to national sovereignty and economic security,' the spokesperson added. ARC earlier told The Lever that TIP 'was established after the September 11 terrorist attacks to provide certain data to law enforcement … for the purpose of national security matters' and criminal probes. The Independent has contacted ARC and CBP for comment.
